Unleash IO's leading product, UIO-512, is an oncolytic adenovirus armed with GM-CSF, triggering an immune response towards the tumor. It is specifically designed for ovarian cancer, with potential applications in glioblastoma, melanoma, and pancreatic cancer. Promising pre-clinical results have been published in top-ranked peer-reviewed publications. Unleash IO is raising $3.5M for a phase I/II clinical trial in ovarian cancer.